Novavax, Inc.’s stock price jumped +7.6% in the latest trading session. The climb was accompanied by a trading volume higher than usual. This follows the biotech company's recent announcement of the initiation of phase 2 clinical trial of its flu vaccine NanoFlu in older adults.
What's more,Novavax's current ratio - a metric of how well a company can meet its short-term obligations - is at 4.50x, which is higher than some of its peers GlaxoSmithKline (0.90x) Novartis (1.10x) and Sanofi (1.20x) as suggested by a Market Realist report.